| Literature DB >> 32788855 |
Marina Tommasini C Sambuy1, Hugo A Nakamoto1, Raul Bolliger1, Rames Mattar1, Marcelo R Rezende1, Teng Hsiang Wei1.
Abstract
OBJECTIVE: Dupuytren's disease is a genetic disorder related to the proliferation of myofibroblasts. The pluripotent property of stem cells present in adipose tissue inhibits myofibroblast proliferation. Our study sought to evaluate the effect of stem cell-rich fat grafts in patients that underwent limited fasciotomy.Entities:
Keywords: Adipose Tissue; Clinical Trial; Dupuytren Contracture; Fasciotomy; Randomized Controlled Trial; Stem Cells
Year: 2020 PMID: 32788855 PMCID: PMC7405848 DOI: 10.1590/1413-785220202804233522
Source DB: PubMed Journal: Acta Ortop Bras ISSN: 1413-7852 Impact factor: 0.513
Preoperative TPED evaluation of Tubiana classification.
| Groups | ||||
|---|---|---|---|---|
| Control group | Fat group | |||
| Tubiana Stage | N | % | N | % |
| I (0º-45º) | 5 | 21% | 4 | 19% |
| II (45º-90º) | 10 | 42% | 11 | 52% |
| III (90º-135º) | 8 | 33% | 4 | 19% |
| IV (≥ 135º) | 1 | 4% | 2 | 10% |
| Total | 24 | 100% | 21 | 100% |
TPED (Total Passive Extension Deficit) = Passive Extension Deficit of MF + IFP + IFD
Figure 1Flow diagram detailing group allocation.
Figure 2Open limited fasciotomy. (Upper pictures), preoperative clinical aspect demonstrating contracture of the 5th finger, anterior view and profile view; (lower left), intraoperative clinical aspect; (lower right), clinical aspect after skin closure demonstrating complete extension of the finger.
Figure 3Process of liposuction of fat with thin cannulas. (Upper left), abdomen incision where the liposuction was performed; (upper right), aspirating microcannulas with fat; (bottom left), fat centrifuging; (lower right), fat already injected into the space previously occupied by the cord.
Intrinsic patient variables and categorical data.
| Groups | ||||||
|---|---|---|---|---|---|---|
| Control group | Fat group | p | ||||
| N | % | N | % | |||
| Gender | Male | 20 | 83% | 14 | 67% | |
| Female | 4 | 17% | 7 | 33% | ||
| Total | 24 | 100% | 21 | 100% | 0.176 | |
| Dominant side | Yes | 13 | 54% | 7 | 33% | |
| No | 11 | 46% | 14 | 67% | ||
| Total | 24 | 100% | 21 | 100% | 0.212 | |
| Presence of nodules | Yes | 23 | 96% | 19 | 90% | |
| No | 1 | 4% | 2 | 10% | ||
| Total | 24 | 100% | 21 | 100% | 0.592 | |
| Presence of cords | Yes | 24 | 100% | 19 | 90% | |
| No | 0 | 0% | 2 | 10% | ||
| Total | 24 | 100% | 21 | 100% | 0.212 | |
Evaluation of pain level according to VAS during follow-up.
| N | Median | Minimum | Maximum | p | |
|---|---|---|---|---|---|
|
| |||||
| Control | 24 | 2 | 0 | 9 | 0.616 |
| With fat | 21 | 5 | 0 | 9 | |
|
| |||||
| Control | 24 | 0 | 0 | 5 | 0.045* |
| With fat | 21 | 2 | 0 | 9 | |
|
| |||||
| Control | 24 | 0 | 0 | 5 | 0.487 |
| With fat | 21 | 0 | 0 | 9 | |
|
| |||||
| Control | 24 | 0 | 0 | 5 | 0.864 |
| With fat | 21 | 0 | 0 | 9 |
N: number of patients; p: level of significance; *: statistical significance (p < 0.05).
Results of the measurement of TPED during the follow-up.
| N | Median | Minimum | Maximum | p | |
|---|---|---|---|---|---|
|
| |||||
| Control | 24 | 77.50 | 35 | 150 | 0.784 |
| With Fat | 21 | 75.00 | 25 | 155 | |
|
| |||||
| Control | 24 | 15.00 | 0 | 55 | 0.198 |
| With Fat | 21 | 25 | 0 | 65 | |
|
| |||||
| Control | 24 | 10.00 | 0 | 45 | 0.101 |
| With Fat | 21 | 15.00 | 0 | 130 | |
|
| |||||
| Control | 24 | 10.00 | 0 | 60 | 0.151 |
| With Fat | 21 | 25.00 | 0 | 135 |
N: number of patients; p: level of significance.
Figure 4Results of the TPED measurement during the follow-up.
BMHQ score results during follow-up.
| N | Median | Minimum | Maximum | p | |
|---|---|---|---|---|---|
|
| |||||
| Control | 24 | 55.20 | 11.13 | 89.58 | 0.241 |
| With Fat | 21 | 60.41 | 27.08 | 89.58 | |
|
| |||||
| Control | 24 | 79.16 | 43.75 | 97.91 | 0.121 |
| With Fat | 21 | 23.66 | 22.72 | 100.00 | |
|
| |||||
| Control | 24 | 92.70 | 50.00 | 100.00 | 0.040* |
| With Fat | 21 | 83.33 | 25.00 | 100.00 | |
|
| |||||
| Control | 24 | 91.28 | 64.58 | 100.00 | 0.047* |
| With Fat | 21 | 87.50 | 43.75 | 96.03 |
N: number of patients; p: level of significance; *: statistical significance (p < 0.05).
Figure 5BMHQ score results during follow-up.
Postoperative complications during follow-up.
| Groups | |||||
|---|---|---|---|---|---|
| Control group | Fat group | p | |||
| Intercurrences | N | % | N | % | |
| Infection | 0 | 0% | 1 | 5% | |
| Dehiscence | 1 | 4% | 2 | 10% | |
| Hematoma | 0 | 0% | 1 | 5% | |
| CRPS | 1 | 4% | 4 | 19% | |
| Hypertrophic scar | 0 | 0% | 1 | 5% | |
| Total | 2 | 8% | 9 | 43% | 0.019 |
N: number of patients; p: level of significance.
Figure 6Postoperative complications during follow-up.